tm logo
AB CHECK
Live/Registered
REGISTERED

on 08 Aug 2023

Last Applicant/ Owned by

Teslova 3

Plzen

CZ

30100

Serial Number

88073859 filed on 10th Aug 2018

Registration Number

7133412 registered on 08th Aug 2023

in the Principal Register

Correspondent Address

Karen L. Elbing

CLARK+ELBING LLP

101 FEDERAL STREET, 15TH FLOOR

BOSTON, MA 02110

Filing Basis

1. intent to use

2. use application currently

Disclaimer

"AB" OR "CHECK"

AB CHECK

Scientific and technological services and research projects for the preparation of peptide and antibody libraries, namely, chemical analysis; scientific and technological services and research projects for the identification and characterisation of binding molecules, namely, in the field of antibody discovery, antibody research and antibody optimization in the nature of working on and evaluation oRead More

Classification Information


Class [042]
Computer & Software Services & Scientific Services


Scientific and technological services and research projects for the preparation of peptide and antibody libraries, namely, chemical analysis; scientific and technological services and research projects for the identification and characterisation of binding molecules, namely, in the field of antibody discovery, antibody research and antibody optimization in the nature of working on and evaluation of chemical analyses; scientific and technological services and research projects for the preparation, identification and characterisation of peptides and antibodies, namely, medical research in the field of antibody discovery, antibody research and antibody optimization; scientific and technological services and research projects for the preparation and identification of recombinant antibodies, single-chain antibodies, diabodies, tandabs, flexibodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole immunoglobulins, and antibody fragments, in particular Fab and scFv fragments, and of nucleic acid sequences coding for these molecules, namely, in the field of antibody discovery, antibody research and antibody optimization, namely, scientific research in the field of antibodies; scientific and technological services and research projects in relation to antibody discovery, namely, medical research in the field of antibody research and drug design; scientific and technological services and research projects in relation to screening of natural, engineered and immunized libraries, namely, medical research in the field of antibody discovery for scientific research services; scientific and technological services and research projects in relation to screening of antibody libraries, namely, in the field of antibody discovery for scientific research services; scientific and technological services and research projects in relation to phage display, phage panning and yeast display vectors, namely, in the field of antibody discovery in the nature of chemical analysis; scientific and technological services and research projects in relation to next-generation yeast display and antibody selection process, namely, in the field of antibody discovery in the nature of chemical analysis; scientific and technological services and research projects in relation to the upstream enrichment of target-specific candidates and batch cloning into yeast-display vectors in the nature of research and development services in the field of antibodies; scientific and technological services in relation to drug discovery by high throughput screen and antibody delivery for therapeutic application, namely, scientific research in the field of antibody research and drug design; scientific and technological services and research projects in relation to batch-cloning and screening of natural, engineered and immunized libraries, namely, scientific research in the field of antibodies and antibody optimization; scientific and technological services and research projects in relation to batch-cloning and screening of antibody libraries, namely, scientific research in the field of antibodies and antibody optimization; scientific and technological services and research projects in relation to antibody development strategies, namely, scientific research in the field of antibody research and antibody optimization; scientific and technological services and research projects in relation to the optimization, maturation and humanization of antibody drug candidates, namely, in the field of antibody research and drug design; scientific and technological services and research projects in relation to multi-factor antibody optimization, namely, scientific research in the field of antibody research and drug design; scientific and technological services and research projects in relation to the optimization of antibody binding affinity, antibody stability, species cross-reactivity, specificity, developability, producibility, and human properties, namely, scientific research in the field of antibody research and antibody optimization; scientific and technological services and research projects in relation to human and non-human lead antibody technology, namely, scientific research in the field of antibody research and antibody optimization


First Use Date in General

27th Sep 2021

First Use Date in Commerce

27th Sep 2021

Mark Details


Serial Number

No 88073859

Mark Type

No Service Mark

Attorney Docket Number

No 50125-T89001

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Design Code(s)

26.01.21 -

Circles that are totally or partially shaded

26.01.31 -

Five or more circles

26.11.09 -

Rectangles made of geometric figures, objects, humans, plants or animals

Description of Design Search

The mark consists of letters "AB" and "CHECK" separated by an array of circles.

Legal History


Show more

Status DateAction Taken
08th Aug 2023REGISTERED-PRINCIPAL REGISTER
08th Aug 2023NOTICE OF REGISTRATION CONFIRMATION EMAILED
06th Jul 2023NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
05th Jul 2023ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
09th Jun 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
08th Jun 2023SOU EXTENSION 5 GRANTED
08th Jun 2023STATEMENT OF USE PROCESSING COMPLETE
30th May 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
24th May 2023TEAS STATEMENT OF USE RECEIVED
24th May 2023TEAS EXTENSION RECEIVED